Subscribe To
ENVB / Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?
ENVB News
By InvestorPlace
May 18, 2023
Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?
Enveric Biosciences (NASDAQ: ENVB ) stock is enlivened amid an otherwise soft early afternoon session on Wall Street, delivering triple-digit percenta more_horizontal
By Business Wire
February 22, 2023
Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the d more_horizontal
By Business Wire
February 1, 2023
Enveric Biosciences to Present at the BIO CEO & Investor Conference
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the more_horizontal
By Business Wire
December 21, 2022
Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the more_horizontal
By Proactive Investors
March 15, 2022
Enveric Biosciences touts the publication of four patent applications for psychedelic-inspired drug candidates
Enveric Biosciences (NASDAQ:ENVB) Inc announced that the company's first four Patent Cooperation Treaty (PCT) applications for the tryptamine family o more_horizontal
By Proactive Investors
March 1, 2022
Enveric Biosciences files portfolio of patent applications for tryptamine derivatives
Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based deriv more_horizontal
By Proactive Investors
March 1, 2022
Enveric Biosciences files portfolio of patent applications for tryptamine derivatives
Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based deriv more_horizontal
By Proactive Investors
March 1, 2022
Enveric Biosciences files portfolio of patent applications for tryptamine derivatives
Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based deriv more_horizontal